Break it Down: Orthocell books first sales revenue in US for Remplir

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Tylah Tully takes a look at Orthocell (ASX:OCC), who have achieved first US revenue from Remplir, its flagship nerve repair product, after the company locked in FDA approval in April.

Tune in to hear all about it.

While Orthocell is a Stockhead advertiser, it did not sponsor this content.